Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal cenegermin for subacute moderate to severe traumatic brain injury
2025-522692-29-00Phase 2Authorised
- Sponsor
- Dompé
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing Intranasal cenegermin with Vehicle control (2 arms). Primary endpoint: Incidence of treatment-emergent serious and non-serious adverse events through 6 months. Planned start Jul 2026; status: authorised.
02
Drugs
cenegermin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2025-522692-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522692-29-00.